Federal Circuit Affirms Patent Priority for PHMB-Based Wound Treatment in First AIA Derivation Review
核心洞察
The Federal Circuit upheld a Patent Trial and Appeal Board ruling granting priority to Marc Selner's patent application for a wound-treatment invention containing polyhexamethylene biguanide (PHMB) over Global Health Solutions LLC (搜索)'s competing claim.
This case represents the Federal Circuit's first review of an AIA derivation proceeding, establishing new precedent for patent priority disputes under the America Invents Act's first-to-file system.
The court clarified that under AIA derivation proceedings, the focus shifts from determining first-to-invent to whether the petitioner conceived and communicated the invention before the respondent filed their application.
The Federal Circuit has affirmed a Patent Trial and Appeal Board decision granting patent priority to Marc Selner for a wound-treatment invention containing polyhexamethylene biguanide (PHMB), marking the court's first review of an AIA derivation proceeding and establishing important precedent for patent disputes under the America Invents Act.
In Global Health Solutions LLC (搜索) v. Marc Selner, the appeals court upheld the PTAB's ruling favoring Selner's patent application over Global Health Solutions LLC's competing claim to the same PHMB-based wound treatment (搜索) technology. The two patent applications covering identical subject matter were filed days apart, with Selner filing first.
AIA Derivation Proceedings Set New Standard
The Federal Circuit used this case to clarify how derivation claims function under the America Invents Act's first-to-file system, distinguishing them from pre-AIA procedures. The court explained that "the required elements of a derivation claim have not changed other than to the extent necessary to reflect the transition from a first-to-invent to a first-to-file system of patent administration."
Under the new framework, "because we no longer focus on who is the first-to-invent, the inquiry in an AIA derivation proceeding centers on whether the petitioner conceived and communicated the invention before the respondent filed his application," the court stated.
The ruling establishes that petitioners in AIA derivation proceedings must produce evidence showing both conception of the claimed invention and communication of that conception to the respondent prior to the respondent's patent filing. Conversely, respondents need only prove "independent conception prior to having received the relevant communication from the petitioner."
Independent Conception Supported by Substantial Evidence
Global Health Solutions had filed a derivation petition against Selner, contending that Selner derived the PHMB wound treatment (搜索) invention from another inventor listed on GHS's patent application. However, the Federal Circuit found that substantial evidence supported the Board's determination of Selner's independent conception.
The court noted that emails and metadata related to those emails provided adequate corroboration for Selner's testimony regarding his independent development of the polyhexamethylene biguanide-based treatment. This evidence was sufficient to demonstrate that Selner conceived of the invention independently, without deriving it from GHS's inventors.
Procedural Error Deemed Harmless
While acknowledging that the PTAB erred by applying pre-AIA standards focused on first-to-invent rather than the appropriate AIA framework, the Federal Circuit determined this constituted "no more than harmless error." The Board's analysis had correctly determined that Selner "independently conceived" of the PHMB-based wound treatment (搜索), which was the crucial finding under either standard.
The court rejected several of GHS's arguments, including claims that the Board improperly shifted the burden of proof and failed to address whether simultaneous conception and reduction to practice was required. The Federal Circuit confirmed that actual reduction to practice was not necessary for complete conception of the invention at issue.
Implications for Patent Priority Disputes
This decision clarifies that "under the AIA, unlike before, the inventor who files first will retain patent rights as long as he did not derive his claimed invention from another." This represents a significant shift in how patent priority disputes are resolved, emphasizing the importance of filing date while maintaining protections against derivation.
The ruling also rejected GHS's alternative request for remand to consider whether one of their inventors should be listed as a co-inventor on Selner's patent, noting that GHS failed to comply with Board requirements for contested inventorship correction requests.
The Federal Circuit's decision in this landmark AIA derivation case provides important guidance for pharmaceutical and medical device companies navigating patent priority disputes under the current first-to-file system, particularly for therapeutic innovations like PHMB-based wound treatments.